IP Library Granted Patent US 8,569,573
Granted Patent B2
US 8,569,573 · App. 12/663,219 · Granted Oct 29, 2013

Method of expanding human hepatocytes in vivo

Inventors: Markus Grompe (Portland, OR); Hisaya Azuma (Tokyo, JP); Muhsen Al-Dhalimy (Beaverton, OR); Mark A. Kay (Los Altos, CA)
Assignees: Oregon Health & Science University; The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,569,573
App. No.
12/663,219
Granted
Oct 29, 2013
Kind
B2
Abstract

Described herein is a method of expanding human hepatocytes in vivo using an immunodeficient mouse which is further deficient in fumarylacetoacetate hydrolase (Fah). The method comprises transplanting human hepatocytes into the immunodeficient and Fah-deficient mice, allowing the hepatocytes to expand and collecting the expanded human hepatocytes. The method also allows serial transplantation of the human hepatocytes into secondary, tertiary, quaternary or additional mice. Also provided are mutant mice comprising homozygous deletions or point mutations in the Fah, Rag2 and Il2rg genes.

Claims (29)

1. A method of expanding human hepatocytes in vivo, comprising:

i) transplanting human hepatocytes into a Rag2 −/− /Il2rg −/− mouse, wherein the mouse is deficient for expression of Fah; and

ii) allowing the human hepatocytes to expand for at least about two weeks, thereby expanding the human hepatocytes.

2. The method of claim 1 , wherein the mouse is a Fah −/− /Rag2 −/− /Il2rg −/− (FRG) mouse.

3. The method of claim 1 , wherein the mouse is a Fah pm /Rag2 −/− /Il2rg −/− (F pm RG) mouse.

4. The method of claim 1 , wherein a vector encoding human urokinase is administered to the mouse prior to transplanting the human hepatocytes.

5. The method of claim 4 , wherein the urokinase is a secreted form of urokinase.

6. The method of claim 4 , wherein the urokinase is a non-secreted form of urokinase.

7. The method of claim 1 , wherein the mouse is administered 2-(2-nitro-4-trifluoro-methyl-benzoyl)-1,3 cyclohexanedione (NTBC) prior to hepatocyte transplantation.

8. The method of claim 7 , wherein the NTBC is administered at a dose of about 0.05 mg/kg/day to about 0.10 mg/kg/day.

9. The method of claim 1 , wherein transplanting the human hepatocytes comprises injecting the human hepatocytes into the spleen or portal vein of the mouse.

10. The method of claim 1 , wherein the transplanted human hepatocytes were isolated from the liver of an organ donor, isolated from a surgical resection, or derived from a stem cell, monocyte or amniocyte.

11. The method of claim 1 , wherein the transplanted human hepatocytes were cryopreserved prior to transplantation.

12. The method of claim 2 , further comprising depleting macrophages from the FRG mouse prior to hepatocyte transplantation.

13. A genetically modified mouse whose genome is homozygous for deletions or one or more point mutations in the Fah, Rag2 and Il2rg genes such that the deletions or point mutations result in loss of expression of functional FAH, RAG-2 and IL-2Rγproteins, wherein the mouse is immunodeficient and exhibits decreased liver function, and wherein human hepatocytes can be expanded in the mouse.

14. The mouse of claim 13 , wherein the deletions or point mutations result in the complete loss of B cells, T cells and NK cells in the mouse.

15. The mouse of claim 13 , wherein the mouse is a FRG mouse.

16. The mouse of claim 13 , wherein the mouse is a F pmRG mouse.

17. The mouse of claim 13 , wherein the mouse expresses human urokinase.

18. The mouse of claim 17 , wherein the urokinase is a secreted form of urokinase.

19. The mouse of claim 17 , wherein the urokinase is a non-secreted form of urokinase.

20. The mouse of claim 17 , wherein expression of human urokinase results from incorporation of a transgene encoding human urokinase into the genome of the mouse.

21. The mouse of claim 17 , wherein expression of human urokinase results from administration of a vector encoding human urokinase.

22. The method of claim 1 , wherein the human hepatocytes are isolated human hepatocytes.

23. The method of claim 1 , further comprising collecting human hepatocytes from the mouse.

24. The method of claim 23 , wherein the human hepatocytes are collected from the liver of the mouse.

25. The method of claim 23 , further comprising expanding the collected human hepatocytes by serial transplantation.

26. The method of claim 1 , further comprising collecting a biological sample from the mouse.

27. The method of claim 26 , wherein the biological sample is a blood, urine, cell or tissue sample.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 29, 2011
From: OREGON HEALTH AND SCIENCE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026820/0831 →
Continuity (2)
Provisional Application 60933432 · Jun 5, 2007
Related Publication 20100325747A1 · Dec 23, 2010